U052 - Melanoma and the Genes: Optimizing Patient Management in the Age of Molecular Testing
Sunday, February 18; 7:00 AM - 8:00 AM
Following this course, the attendee should be able to:
- Identify patients who would benefit from germline genetic testing to identify inherited melanoma susceptibility, and distinguish between germline and somatic mutation testing to improve patient counseling.
- Examine the utility of ancillary testing modalities for the distinction of benign versus malignant melanocytic proliferations in skin biopsies.
- Recognize the available molecular tests for management of advanced melanoma patients.
An increasing number of genetic and molecular tests are being developed and/or utilized for the management of melanoma patients. Dermatologists should be familiar with scenarios in which such testing would be beneficial. During this session, we will discuss the relevance of clinical testing for cancer susceptibility genes, as well as molecular assays which may aid in establishing melanoma diagnosis, prognosis, and response to therapy (including CGH, FISH, and next generation sequencing panels). This session is intended for a broad audience, from dermatology trainees to established practitioners.
- Chu, Emily Y., MD, PhD: no financial relationships exist with commercial interests.
Sunday, February 18
Dr. Chu / Update on Genetic Testing for Melanoma
Dr. Tetzlaff / Molecular changes informing the diagnosis of melanocytic tumors